{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:37:47Z","timestamp":1772746667123,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1124\/mol.113.088963","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T03:37:56Z","timestamp":1384313876000},"page":"198-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Salicylate, a Catalytic Inhibitor of Topoisomerase II, Inhibits DNA Cleavage and Is Selective for the \u03b1 Isoform"],"prefix":"10.1016","volume":"85","author":[{"given":"Jason T.","family":"Bau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline A.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebba U.","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/mol.113.088963_bib1","series-title":"DNA Binders and Related Subjects","first-page":"55","article-title":"Cyanine dye\u2013DNA interactions: intercalation, groove binding, and aggregation","author":"Armitage","year":"2005"},{"key":"10.1124\/mol.113.088963_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q","article-title":"Eukaryotic DNA topoisomerase II beta","volume":"20","author":"Austin","year":"1998","journal-title":"Bioessays"},{"key":"10.1124\/mol.113.088963_bib3","doi-asserted-by":"crossref","first-page":"15739","DOI":"10.1074\/jbc.270.26.15739","article-title":"Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta","volume":"270","author":"Austin","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/mol.111.077537","article-title":"The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the \u03b1 isoform of human DNA topoisomerase II","volume":"82","author":"Auzanneau","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.113.088963_bib5","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1073\/pnas.0704002104","article-title":"Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies","volume":"104","author":"Azarova","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.088963_bib6","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.1073\/pnas.96.24.13685","article-title":"Topoisomerase II drives DNA transport by hydrolyzing one ATP","volume":"96","author":"Baird","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.088963_bib7","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1021\/bi7000664","article-title":"Bioflavonoids as poisons of human topoisomerase II alpha and II beta","volume":"46","author":"Bandele","year":"2007","journal-title":"Biochemistry"},{"key":"10.1124\/mol.113.088963_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-60761-340-4_4","article-title":"Cleavage of plasmid DNA by eukaryotic topoisomerase II","volume":"582","author":"Bandele","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1124\/mol.113.088963_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bcp.2010.10.009","article-title":"Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha","volume":"81","author":"Bau","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.113.088963_bib10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.1201538","article-title":"Positive supercoiling of mitotic DNA drives decatenation by topoisomerase II in eukaryotes","volume":"331","author":"Baxter","year":"2011","journal-title":"Science"},{"key":"10.1124\/mol.113.088963_bib11","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2174\/1381612013397113","article-title":"Intercalators as anticancer drugs","volume":"7","author":"Bra\u00f1a","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1124\/mol.113.088963_bib12","first-page":"283","article-title":"Topoisomerase II-mediated cleavage of plasmid DNA","volume":"95","author":"Burden","year":"2001","journal-title":"Methods Mol Biol"},{"key":"10.1124\/mol.113.088963_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6769-9-1","article-title":"Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue","volume":"9","author":"Ch\u00e8ne","year":"2009","journal-title":"BMC Chem Biol"},{"key":"10.1124\/mol.113.088963_bib14","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.1832879100","article-title":"Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187","volume":"100","author":"Classen","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.088963_bib15","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1073\/pnas.1204406109","article-title":"Model for MLL translocations in therapy-related leukemia involving topoisomerase II\u03b2-mediated DNA strand breaks and gene proximity","volume":"109","author":"Cowell","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.088963_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Cvetkovi\u0107","year":"2005","journal-title":"Drugs"},{"key":"10.1124\/mol.113.088963_bib17","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1096\/fj.01-0259com","article-title":"Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts","volume":"15","author":"Deng","year":"2001","journal-title":"FASEB J"},{"key":"10.1124\/mol.113.088963_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.molcel.2010.07.024","article-title":"Replication termination at eukaryotic chromosomes is mediated by Top2 and occurs at genomic loci containing pausing elements","volume":"39","author":"Fachinetti","year":"2010","journal-title":"Mol Cell"},{"key":"10.1124\/mol.113.088963_bib19","doi-asserted-by":"crossref","first-page":"17643","DOI":"10.1074\/jbc.273.28.17643","article-title":"Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage","volume":"273","author":"Fortune","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib20","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1073\/pnas.96.21.12168","article-title":"XK469, a selective topoisomerase IIbeta poison","volume":"96","author":"Gao","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.088963_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.embor.7400465","article-title":"Topoisomerase II-DNA complexes trapped by ICRF-193 perturb chromatin structure","volume":"6","author":"Germe","year":"2005","journal-title":"EMBO Rep"},{"key":"10.1124\/mol.113.088963_bib22","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1038\/emboj.2009.223","article-title":"A non-canonical function of topoisomerase II in disentangling dysfunctional telomeres","volume":"28","author":"Germe","year":"2009","journal-title":"EMBO J"},{"key":"10.1124\/mol.113.088963_bib23","first-page":"161","article-title":"Drug-DNA interactions","volume":"95","author":"Graves","year":"2001","journal-title":"Methods Mol Biol"},{"key":"10.1124\/mol.113.088963_bib24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1006\/bbrc.1996.0162","article-title":"Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum)","volume":"218","author":"Handa","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/mol.113.088963_bib25","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1021\/bi9729108","article-title":"Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 2. Kinetic mechanism for the sequential hydrolysis of two ATP","volume":"37","author":"Harkins","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/mol.113.088963_bib26","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1126\/science.1215327","article-title":"The ancient drug salicylate directly activates AMP-activated protein kinase","volume":"336","author":"Hawley","year":"2012","journal-title":"Science"},{"key":"10.1124\/mol.113.088963_bib27","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1124\/mol.106.027714","article-title":"Salvicine functions as novel topoisomerase II poison by binding to ATP pocket","volume":"70","author":"Hu","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.113.088963_bib28","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1126\/science.1127196","article-title":"A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription","volume":"312","author":"Ju","year":"2006","journal-title":"Science"},{"key":"10.1124\/mol.113.088963_bib29","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/bi201159b","article-title":"Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions","volume":"51","author":"Ketron","year":"2012","journal-title":"Biochemistry"},{"key":"10.1124\/mol.113.088963_bib30","first-page":"51","article-title":"Topoisomerase II-catalyzed ATP hydrolysis as monitored by thin-layer chromatography","volume":"95","author":"Kingma","year":"2001","journal-title":"Methods Mol Biol"},{"key":"10.1124\/mol.113.088963_bib31","doi-asserted-by":"crossref","first-page":"13948","DOI":"10.1074\/jbc.275.18.13948","article-title":"Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon","volume":"275","author":"Kurz","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(03)00058-5","article-title":"Catalytic topoisomerase II inhibitors in cancer therapy","volume":"99","author":"Larsen","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1124\/mol.113.088963_bib33","doi-asserted-by":"crossref","first-page":"26418","DOI":"10.1074\/jbc.271.42.26418","article-title":"Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors","volume":"271","author":"Lassota","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1124\/mol.113.088963_bib35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ncb1828","article-title":"Topoisomerase IIalpha controls the decatenation checkpoint","volume":"11","author":"Luo","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1124\/mol.113.088963_bib36","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1074\/jbc.275.4.2613","article-title":"Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193","volume":"275","author":"Morris","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/mol.113.088963_bib38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/mol.113.088963_bib39","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1021\/bi00441a005","article-title":"Effect of antineoplastic agents on the DNA cleavage\/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide","volume":"28","author":"Osheroff","year":"1989","journal-title":"Biochemistry"},{"key":"10.1124\/mol.113.088963_bib40","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1021\/bi00388a018","article-title":"Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form","volume":"26","author":"Osheroff","year":"1987","journal-title":"Biochemistry"},{"key":"10.1124\/mol.113.088963_bib41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0006-2952(01)00759-6","article-title":"Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John\u2019s wort (Hypericum perforatum)","volume":"62","author":"Peebles","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.113.088963_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1124\/mol.113.088963_bib43","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1093\/nar\/15.16.6713","article-title":"DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators","volume":"15","author":"Pommier","year":"1987","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/mol.113.088963_bib44","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1158\/1535-7163.MCT-07-0147","article-title":"Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain","volume":"6","author":"Qin","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/mol.113.088963_bib45","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1021\/bi00065a016","article-title":"Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II","volume":"32","author":"Robinson","year":"1993","journal-title":"Biochemistry"},{"key":"10.1124\/mol.113.088963_bib46","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1021\/bi00221a012","article-title":"Effects of antineoplastic drugs on the post-strand-passage DNA cleavage\/religation equilibrium of topoisomerase II","volume":"30","author":"Robinson","year":"1991","journal-title":"Biochemistry"},{"key":"10.1124\/mol.113.088963_bib47","first-page":"75","article-title":"Filter binding assays for topoisomerase-DNA complexes","volume":"95","author":"Roca","year":"2001","journal-title":"Methods Mol Biol"},{"key":"10.1124\/mol.113.088963_bib48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0092-8674(92)90558-T","article-title":"The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases","volume":"71","author":"Roca","year":"1992","journal-title":"Cell"},{"key":"10.1124\/mol.113.088963_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nsmb.2388","article-title":"Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity","volume":"19","author":"Schmidt","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"10.1124\/mol.113.088963_bib50","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0022-2836(92)90863-F","article-title":"Mode of action of topoisomerase II-targeting agents at a specific DNA sequence: uncoupling the DNA binding, cleavage and religation events","volume":"228","author":"S\u00f8rensen","year":"1992","journal-title":"J Mol Biol"},{"key":"10.1124\/mol.113.088963_bib51","doi-asserted-by":"crossref","first-page":"23711","DOI":"10.1074\/jbc.M803936200","article-title":"NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform","volume":"283","author":"Toyoda","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib52","doi-asserted-by":"crossref","first-page":"18636","DOI":"10.1074\/jbc.M112.345678","article-title":"Mechanisms for defining supercoiling set point of DNA gyrase orthologs: I. A nonconserved acidic C-terminal tail modulates Escherichia coli gyrase activity","volume":"287","author":"Tretter","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib53","doi-asserted-by":"crossref","first-page":"11920","DOI":"10.1074\/jbc.M411841200","article-title":"Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis","volume":"280","author":"Vaughn","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088963_bib54","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.biocel.2012.03.005","article-title":"DNA topoisomerase II\u03b2: a player in regulation of gene expression and cell differentiation","volume":"44","author":"V\u00e1vrov\u00e1","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/mol.113.088963_bib55","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrm3228","article-title":"All tangled up: how cells direct, manage and exploit topoisomerase function","volume":"12","author":"Vos","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/mol.113.088963_bib56","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ejca.2011.03.022","article-title":"The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium","volume":"47","author":"Vrooman","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1124\/mol.113.088963_bib57","doi-asserted-by":"crossref","first-page":"13371","DOI":"10.1073\/pnas.222543099","article-title":"Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?","volume":"99","author":"Warner","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.088963_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1124\/mol.113.088963_bib59","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24038628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24038628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.113.088963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:18:43Z","timestamp":1739963923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24038628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0026895X24038628"],"URL":"https:\/\/doi.org\/10.1124\/mol.113.088963","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salicylate, a Catalytic Inhibitor of Topoisomerase II, Inhibits DNA Cleavage and Is Selective for the \u03b1 Isoform","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.113.088963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}